Abstract Details

Title Prognostic Factors of Poor Outcome in Idiopathic Intracranial Hypertension

Topic Neuro-ophthalmology/Neuro-otology

Presentation(s) P1 - Poster Session 1 (5:30 PM-6:30 PM)

Poster/Presentation
Number 4-008

Objective Our main goals were to identify these factors and propose therapeutic guidelines and follow-up strategy.

Background The principal goal when managing patients with Idiopathic Intracranial Hypertension (IIH) is to preserve vision and prevent optic nerve atrophy. Since visual function can be severely threatened, it is crucial to evaluate the prognostic factors.

Design/Methods We conducted a retrospective study including all the patients diagnosed with IIH from 2000 to 2016 in the department of neurology. Our cohort was divided into 2 subgroups according to the outcome at six months assessment We compared clinical and investigational results between the two subgroups.

Results We included 106 patients. At 6 months assessment, 27.8% of the patients had poor outcome. Papilloedema resorption was achieved in 68 patients over a mean period of 5.7 months. We demonstrated a significant correlation between the outcome and abrupt onset of symptoms (p=0.006), but not with the other factors: gender, age, body mass index, cerebrospinal fluid opening pressure (CSF OP), papilloedema stage, medical history, MRI findings, the use of corticosteroids and evacuating lumbar puncture. We mentioned that mean initial BMI and CSF OP was higher in patients with optic atrophy (p=0.002, p=0.019 respectively).

Conclusions Given the importance of our findings, all the patients diagnosed with IIH should be managed carefully even in absence of the poor prognostic factors and be kept under long term follow-up. If a visual worsening is detected under medical therapy, a surgical procedure is proposed early before the occurrence of definitive visual sequels.

Authors/Disclosures
PRESENTER	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Chokri A. Mhiri, MD (Habib Bourguiba Hospital)	Prof. Mhiri has received personal compensation for serving as an employee of Hikma. Prof. Mhiri has received personal compensation for serving as an employee of Sanofi Genzyme. Prof. Mhiri has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Prof. Mhiri has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche.

��ɫ��

��ɫ��